IMMUTEP LIMITED - AMER

Immutep Receives Positive EMA Scientific Advice for Further Clinical Development of Efti in MBC Including Phase III

29 Oct 2021 08:00:00 By Nasdaq GlobeNewswire

Immutep Quarterly Activities Report & Appendix 4C

28 Oct 2021 08:00:02 By Nasdaq GlobeNewswire

Immutep to Present Phase II TACTI-002 Data at SITC 2021

01 Oct 2021 08:00:02 By Nasdaq GlobeNewswire

Immutep Receives A$3.4 million R&D Tax Incentive from French Government

29 Sep 2021 08:00:00 By Nasdaq GlobeNewswire

Immutep to Present at Healthcare Investor Conferences

28 Sep 2021 08:00:01 By Nasdaq GlobeNewswire

Immutep to Present Final Overall Survival Data From Phase IIb AIPAC as a Late Breaking Poster Presentation at SITC 2021

21 Sep 2021 08:38:03 By Nasdaq GlobeNewswire

Immutep Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients in TACTI-002

01 Sep 2021 08:00:00 By Nasdaq GlobeNewswire

Immutep’s Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline

31 Aug 2021 08:00:01 By Nasdaq GlobeNewswire

Immutep Announces Chinese Patent Grant for LAG-3 Antagonist Antibody LAG525

27 Aug 2021 08:00:00 By Nasdaq GlobeNewswire

Immutep Reports Dosing of First Patient for Triple Combination (efti + anti-PD-1 + chemo) in INSIGHT-003

05 Aug 2021 08:00:02 By Nasdaq GlobeNewswire

Immutep Quarterly Activities Report

13 Jul 2021 08:00:03 By Nasdaq GlobeNewswire

Immutep receives FDA and IRB approval in the US for Phase IIb TACTI-003 trial in HNSCC

06 Jul 2021 08:00:01 By Nasdaq GlobeNewswire

Immutep Completes a A$60 Million Placement to Expand its Clinical Development and Manufacturing Program into Late-Stage Settings

21 Jun 2021 08:00:00 By Nasdaq GlobeNewswire

Immutep to Evaluate Efti in Triple Combination Therapy Phase I Study with Chemotherapy and an anti-PD-1 Therapy

21 Jun 2021 08:00:00 By Nasdaq GlobeNewswire

Immutep Reveals a New Anti-LAG-3 Research Program

08 Jun 2021 08:00:01 By Nasdaq GlobeNewswire

Immutep Reports Positive Data from its TACTI-002 Phase II Study of LAG-3 Therapy, Efti, at ASCO 2021

04 Jun 2021 08:00:01 By Nasdaq GlobeNewswire

Immutep Reports Positive Final Data from the INSIGHT-004 Phase I Study of LAG-3 Therapy, Efti, at ASCO 2021

04 Jun 2021 08:00:00 By Nasdaq GlobeNewswire

Immutep Secures Second European Patent For Eftilagimod Alpha, A Soluble LAG-3 Protein, In Combination With A PD-1 Pathway Inhibitor

02 Jun 2021 08:00:02 By Nasdaq GlobeNewswire

Immutep Enters Into A New Collaboration With Merck KGaA, Darmstadt, Germany For LAG-3 Therapy, Efti

01 Jun 2021 08:00:01 By Nasdaq GlobeNewswire

Immutep Granted Chinese Patent For Eftilagimod Alpha In Chemo-Immunotherapy Combination

26 May 2021 08:00:01 By Nasdaq GlobeNewswire